Table 5. Adverse events of patients receiving TILA-TACE or cTACE.

Adverse events*	TILA-TACE	cTACE†
Pain	5 out of 30	3 out of 27
Fever (≥38.5)‡	13 out of 30	9 out of 27

* The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.

^† Patients were retrospectively retrieved from our database.

^‡ Mild fever occurred to all patients.